NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD
39.48
+0.33 (+0.84%)
The current stock price of CYTK is 39.48 USD. In the past month the price decreased by -8.4%. In the past year, price decreased by -41.55%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 498 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
CYTOKINETICS INC
350 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Robert I. Blum
Employees: 423
Company Website: https://cytokinetics.com/
Investor Relations: https://ir.cytokinetics.com
Phone: 16506243000
The current stock price of CYTK is 39.48 USD. The price increased by 0.84% in the last trading session.
The exchange symbol of CYTOKINETICS INC is CYTK and it is listed on the Nasdaq exchange.
CYTK stock is listed on the Nasdaq exchange.
27 analysts have analysed CYTK and the average price target is 80.58 USD. This implies a price increase of 104.1% is expected in the next year compared to the current price of 39.48. Check the CYTOKINETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CYTOKINETICS INC (CYTK) has a market capitalization of 4.67B USD. This makes CYTK a Mid Cap stock.
CYTOKINETICS INC (CYTK) currently has 423 employees.
CYTOKINETICS INC (CYTK) has a support level at 37.87 and a resistance level at 39.49. Check the full technical report for a detailed analysis of CYTK support and resistance levels.
The Revenue of CYTOKINETICS INC (CYTK) is expected to grow by 775.08% in the next year. Check the estimates tab for more information on the CYTK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYTK does not pay a dividend.
CYTOKINETICS INC (CYTK) will report earnings on 2025-05-01, after the market close.
CYTOKINETICS INC (CYTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.26).
The outstanding short interest for CYTOKINETICS INC (CYTK) is 12.21% of its float. Check the ownership tab for more information on the CYTK short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CYTK. Both the profitability and financial health of CYTK have multiple concerns.
Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -5.26. The EPS increased by 3.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.06% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 82% to CYTK. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -11.25% and a revenue growth 775.08% for CYTK